June 30th 2025
Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.
Venetoclax/Azacitidine Shows Promise for Relapse Prevention in High-Risk MDS and AML
March 9th 2024Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Read More
From Stigma to Solutions: MBGH Panel Explores Mental Health Paradigm Shift in the Workplace
March 8th 2024The critical issue of mental health in the workplace was discussed by experts in the field at the recent Midwest Business Group on Health (MBGH) Mental Health Forum, shedding light on the growing concern surrounding alcohol use disorder and the pressing need for innovative therapies.
Read More
Improving Glycemic Control in Diabetes Through Virtual Interdisciplinary Rounds
Patients with diabetes whose providers received advice from remote, virtual interdisciplinary rounds had a greater 1-year reduction in hemoglobin A1c than comparable patients.
Read More
Dr Jennifer Vaughn: Patients With MPN, MDS Should Discuss Long-Term Priorities Upfront
March 1st 2024For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Watch
PROs May Successfully Risk Stratify Patients With Cutaneous Chronic GVHD
March 1st 2024Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).
Read More
CA-125 Shows Poor Concordance With Radiologic Progression in Ovarian Cancer
March 1st 2024Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.
Read More
Analysis Identifies Gut Microbiota Affecting Risk of MG
February 29th 2024The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.
Read More
Children With SCD Exhibit Distinctive Palatal Rugae Patterns
February 29th 2024A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.
Read More
What Are the Steps to Quality Improvement in Cancer Care?
February 29th 2024Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.
Read More